Improving Diagnosis of Bladder Cancer

该项目的长期目标是改进对一种常见人类癌症的检测 通过非侵入性排尿试验在膀胱中出现。膀胱癌是全世界最常见的癌症。 男性和5例最常见，约70,500例新病例和14,600例死亡 2009年在美国。据估计，近30万名患者在医院接受定期监测 美国通过非侵入性(尿液)和微创性(膀胱术， 膀胱镜检查和活组织检查)技术。因此，新型生物标志物的开发可以检测到 采用非侵入性方法治疗膀胱肿瘤具有重要的临床意义。在这项拨款中，我们建议 对现有多机构极光蛋白A FISH检测生物标记物验证试验的补充 FISH标记和探索极光激酶A在膀胱癌进展中的作用。我们将比较 极光的特异性和敏感性FISH试验辅以一组新的FISH标志物与其他 已知的尿液沉渣非侵入性膀胱癌检测试验，如尿细胞学和 商业化的多染色体FISH试剂盒称为UroVysion，以及NMP22点护理测试。一个 将通过整体器官组织和遗传作图(WOHGM)开发一组新的FISH标记 策略与基于高分辨率(IM)llLumina SNP的基因分型相结合，提供了独特的 与膀胱癌发生平行的基因组改变的年表信息 侵袭性疾病的早期田间效应。我们强有力的初步数据表明，这种方法提供了一个独特的 有机会设计新的生物标志物，以解决膀胱癌发展的特定阶段 沿着这些浅乳头状癌和高级别非乳头状癌的侵袭途径。此外，我们建议 探讨极光激酶A及其常规途径在膀胱癌侵袭过程中的作用 疾病和远处转移。本项目的具体目标如下：具体目标1：开发一种 膀胱癌新型FISH标记物小组。具体目标2：验证一组新的鱼类生物标志物 治疗膀胱癌。具体目标3：研究极光激酶A在膀胱癌生长中的作用 血管生成、侵袭和转移。

The long-term objective of this project is to improve the detection of one of the common human cancers arising in the bladder by non-invasive voided urine-based tests. Bladder cancer is the 4"^ most frequent in men and 5"" most common overall with approximately 70,500 new cases and 14,600 deaths from the disease in 2009 in the United States. It is estimated that nearly 300,000 patients are regularly monitored in the United States through a vanety of non-invasive (urine) and minimally invasive (bladder barbotage, cystoscopy, and biopsy) techniques. Therefore, the development of novel biomarkers that can detect bladder tumors by a non-invasive approach is of major clinical significance. In this grant, we propose to complement the existing Multi-Institutional Aurora kinase A FISH Test Biomarker Validation Trial by novel FISH markers and explore the role of Aurora kinase A in bladder cancer progression. We will compare the specificity and sensitivity of aurora A FISH test complemented by a panel of novel FISH markers with other known noninvasive bladder cancer detection tests for voided urine sediments such as urine cytology and commercially available multi-chromosomal FISH kit known as UroVysion, and NMP22 point-of-care test. A panel of novel FISH markers will be developed by whole-organ histologic and genetic mapping (WOHGM) strategy combined with high resolution (IM) lllumina SNP-based genotyping, which provides unique information on the chronology of genomic alterations that parallel the development of bladder cancer from early field effects to invasive disease. Our strong preliminary data indicate that this approach offers a unique opportunity to design novel biomarkers that may address the specific phases of bladder cancer development along these superficial papillary and high grade nonpapillary Invasive pathways. Moreover, we propose to investigate the role of aurora kinase A and its regular pathway in bladder cancer progression to invasive disease and distant metastasis. The specific aims of this project are as follows: Specific Aim 1: Develop a panel of novel FISH markers for bladder cancer. Specific Aim 2: Validate a novel set of FISH biomarkers for bladder cancer. Specific Aim 3: Investigate the role of Aurora kinase A in bladder cancer growth, angiogenesis, invasion and metastasis.